1. Home
  2. VIRX vs SMX Comparison

VIRX vs SMX Comparison

Compare VIRX & SMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIRX
  • SMX
  • Stock Information
  • Founded
  • VIRX 2007
  • SMX N/A
  • Country
  • VIRX United States
  • SMX Ireland
  • Employees
  • VIRX N/A
  • SMX N/A
  • Industry
  • VIRX Biotechnology: Pharmaceutical Preparations
  • SMX Industrial Machinery/Components
  • Sector
  • VIRX Health Care
  • SMX Technology
  • Exchange
  • VIRX Nasdaq
  • SMX Nasdaq
  • Market Cap
  • VIRX 7.7M
  • SMX 7.6M
  • IPO Year
  • VIRX N/A
  • SMX N/A
  • Fundamental
  • Price
  • VIRX $0.16
  • SMX $0.23
  • Analyst Decision
  • VIRX Buy
  • SMX
  • Analyst Count
  • VIRX 4
  • SMX 0
  • Target Price
  • VIRX $5.00
  • SMX N/A
  • AVG Volume (30 Days)
  • VIRX 2.5M
  • SMX 3.8M
  • Earning Date
  • VIRX 11-13-2024
  • SMX 11-29-2024
  • Dividend Yield
  • VIRX N/A
  • SMX N/A
  • EPS Growth
  • VIRX N/A
  • SMX N/A
  • EPS
  • VIRX N/A
  • SMX 6.43
  • Revenue
  • VIRX N/A
  • SMX N/A
  • Revenue This Year
  • VIRX N/A
  • SMX N/A
  • Revenue Next Year
  • VIRX N/A
  • SMX N/A
  • P/E Ratio
  • VIRX N/A
  • SMX $0.04
  • Revenue Growth
  • VIRX N/A
  • SMX N/A
  • 52 Week Low
  • VIRX $0.13
  • SMX $0.20
  • 52 Week High
  • VIRX $1.31
  • SMX $102.00
  • Technical
  • Relative Strength Index (RSI)
  • VIRX 32.53
  • SMX 23.12
  • Support Level
  • VIRX $0.14
  • SMX $0.20
  • Resistance Level
  • VIRX $0.21
  • SMX $0.29
  • Average True Range (ATR)
  • VIRX 0.01
  • SMX 0.03
  • MACD
  • VIRX -0.00
  • SMX 0.09
  • Stochastic Oscillator
  • VIRX 43.86
  • SMX 22.10

About VIRX Viracta Therapeutics Inc.

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

About SMX SMX (Security Matters) Public Limited Company

SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.

Share on Social Networks: